This is a working overview of Thymosin fraction 5, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-09 and is reviewed periodically as new material appears.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
CKLF-like MARVEL transmembrane domain-containing 5 (CMTM5), previously termed chemokine-like factor superfamily 5 (i.e. CKLFSF5), designates any one of the six protein isoforms (termed CMTM5-v1 to CMTM5-v6) encoded by six different alternative splices of its gene, CMTM5; CMTM5-v1 is the most studied of these isoforms. The CMTM5 gene is located in band 11.2 on the long (i.e. "q") arm of chromosome 14. The CMTM5 isoforms are members of the CKLF-like MARVEL transmembrane domain-containing family (CMTM). This family consists of 9 proteins although most of them are known to have one or more isoforms. These proteins are: chemokine-like factor (i.e. CLF, the founding member of the family) and CEF-like marvel transmembrane domain-containing 1 through 8 (i.e. CMTM1 through CMTM8). All of these proteins as well as the genes responsible for their production (i.e. CKLF and CMTM1 to CMTM8, respectively) have similar structures but vary in their apparent physiological and pathological functions. Preliminary studies suggest that CMTM5-v1 (which cells commonly secrete to the extracellular spaces such as the blood) or an unspecified CMTM5 isoform has various functions including involvements in regulating the autoimmune system, the development of numerous types of cancers, and the cardiovascular system.
=== Brand names === Mianserin is marketed in many countries mainly under the brand name Tolvon. It is also available throughout the world under a variety of other brand names including Athymil, Bonserin, Bolvidon, Deprevon, Lantanon, Lerivon, Lumin, Miansan, Serelan, Tetramide, and Tolvin among others.
=== Mechanism of action === The alkylation mechanism of melphalan is shared by all nitrogen mustards, proceeding through the formation of an aziridinium cation. This highly reactive intermediate interacts with nitrogen atoms in nucleotide bases, generating positively charged adducts. Melphalan chemically modifies DNA nucleotides through alkylation, primarily targeting guanine at the N7 position within the major groove, and to a lesser extent adenine at the N3 position within the minor groove.
Sources: en.wikipedia.org
Cold seeps and hydrothermal vents of deep oceans are communities that do not rely on photosynthesis for food and energy production. These systems are largely driven by chemosynthetic derived energy. Both systems share common characteristics such as the presence of reduced chemical compounds (H2S and hydrocarbonates), local hypoxia or even anoxia, a high abundance and metabolic activity of bacterial populations, and the production of autochthonous, organic material by chemoautotrophic bacteria. Both hydrothermal vents and cold seeps show highly increased levels of metazoan biomass in association with a low local diversity. This is explained through the presence of dense aggregations of foundation species and epizoic animals living within these aggregations. Community-level comparisons reveal that vent, seep, and organic-fall macrofauna are very distinct in terms of composition at the family level, although they share many dominant taxa among highly sulphidic habitats. However, hydrothermal vents and cold seeps also differ in many ways. Compared to the more stable cold seeps, vents are characterized by locally-high temperatures, strongly fluctuating temperatures, pH, sulfide and oxygen concentrations, often the absence of sediments, a relatively young age, and often-unpredictable conditions, such as waxing and waning of vent fluids or volcanic eruptions. Unlike hydrothermal vents, which are volatile and ephemeral environments, cold seeps emit at a slow and dependable rate.
== Specials == 空山鳥語 - kōngshān niǎo yǔ - Birdsong in Hollow Valley 2014 This special consists of three episodes which tells the story of Baifeng and his friend Moya who were assassins for General Ji Wuye, but who turn against him after Baifeng falls for a female assassin, Nong Yu.
=== Semen volume === According to one lab test manual semen volumes between 2.0 mL and 5 mL are normal; WHO regards 1.4 mL as the lower reference limit. Low volume, called hypospermia, may indicate partial or complete blockage of the seminal vesicles, or that the man was born without seminal vesicles. In clinical practice, a volume of less than 1,4 mL in the setting of infertility is most likely due to incomplete ejaculation or partial loss of sample, asides this, patient should be evaluated for hypoandrogenism and obstructions in some parts of the ejaculatory tract, azoospermia, given that it has been at least 48 hours since the last ejaculation to time of sample collection. The human ejaculate is mostly composed of water, 96 to 98% of semen is water. One way of ensuring that a man produces more ejaculate is to drink more liquids. Men also produce more seminal fluid after lengthy sexual stimulation and arousal. Reducing the frequency of sex and masturbation helps increase semen volume. Sexually transmitted diseases also affect the production of semen. Men who are infected with the human immunodeficiency virus (HIV) produce lower semen volume. The volume of semen may also be increased, a condition known as hyperspermia. A volume greater than 6mL may indicate Prostate inflammation. When there's no volume, the condition is named as aspermia, which could be caused by retrograde ejaculation, anatomical or neurological diseases or anti-hypertensive drugs.
Sources: en.wikipedia.org
==== Executive Committee ==== The Executive Committee of the IIR handles the administrative and financial aspects of the daily running of the IIR and meets once per year. It includes one delegate per member country, a president and three to six vice-presidents.
==== Pan Sahel Initiative ==== In 2002, the United States created the Pan Sahel Initiative (PSI) which was aimed at counter-terrorism and enhancing regional peace and security in Mali, Mauritania, Niger and Chad. Green Berets from the 10th SFG attached to Special Operations Command Europe (SOCEUR) of the United States European Command (EUCOM) deployed to Niger and Mali and supervised anti-terror exercises in the Sahara Desert.
== Consensus Development Program == The Consensus Development Program is an initiative focused on gathering expert opinions to establish standards and guidelines in various fields, especially in health and medicine. Developed as a collaborative effort by organizations such as the NIH, the program assembles panels of specialists who assess available evidence on critical topics and form recommendations to guide clinical practice and policy. This method helps ensure that healthcare decisions are informed by the latest scientific research and expert consensus.
The explanation of the extraordinary efficiency is the use of mixtures in the synthetic steps. If in a traditional reaction one compound is coupled with one reactant and one new compound is formed. If a mixture of compounds containing n components is coupled with a single reactant the number of new compounds formed in the single coupling is n. The difference between the traditional and the split and pool synthesis is convincingly shown by the number of coupling steps in the traditional and the split and pool synthesis of 3,2 million pentapeptides. Conventional synthesis: 3,200,000x5=16,000,000 coupling steps cca 40,000 years S&P synthesis: 20x5=100 coupling steps cca 5 days It is possible to conduct the conventional synthesis rational way as is shown in the figure. In this case, the number of coupling cycles is: 20+400+8,000+160,000+3,200,000=3,368,420 cca 9,200 years
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.